Capricor Therapeutics announced on July 29, 2026, that The Lancet has published the final one-year results from its HOPE-3 Phase 3 clinical trial evaluating Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. The publication followed independent peer review and coincided with an FDA Bioresearch Monitoring inspection that concluded with one observational citation. The company also disclosed a statistical model update affecting the left ventricular ejection fraction secondary endpoint analysis.

Key Points

  • NASDAQ: CAPR
  • HOPE-3 Phase 3 trial results for Deramiocel in Duchenne muscular dystrophy published in The Lancet on July 29, 2026, following independent peer review
  • Left ventricular ejection fraction secondary endpoint revised to p=0.09 under updated statistical model, down from previously reported p=0.04; cardiomyopathy subgroup remains nominally significant at p=0.02
  • FDA BIMO inspection completed July 20, 2026, issued one Form FDA 483 observation related to standard operating procedures, documentation, vendor oversight, and audit timeliness; company states observation does not affect data integrity

HOPE-3 Trial Results Achieve Publication in Premier Medical Journal

Capricor Therapeutics disclosed that The Lancet has published the complete one-year efficacy and safety results from the HOPE-3 Phase 3 clinical trial on July 29, 2026. The trial evaluated Deramiocel, the company's investigational cell therapy candidate, in patients with Duchenne muscular dystrophy, a serious genetic neuromuscular disorder. The publication represents a significant milestone as the manuscript underwent independent peer review prior to acceptance, providing external validation of the trial's statistical methodology and the integrity of the findings presented to the medical and investment community.

The filing states that the published results are based on the company's prespecified Statistical Analysis Plan version 3.0 (SAP 3.0). This formalized statistical framework was established prior to final data analysis and represents the company's commitment to transparent, predetermined analytical approaches in evaluating trial outcomes. The peer review process by The Lancet's editorial team adds an additional layer of external scientific scrutiny to the trial design and conclusions.

Updated Statistical Model for Left Ventricular Ejection Fraction Analysis

As part of ongoing dialogue with the FDA regarding the HOPE-3 data and in connection with the peer review process conducted by The Lancet, Capricor identified an update to the statistical model used in its analysis of left ventricular ejection fraction (LVEF), designated as a key secondary endpoint of the trial. The company disclosed that under the revised model, the LVEF endpoint yields a p-value of 0.09, representing a 1.8 percentage point treatment difference. This revision differs from the previously reported result of p=0.04, which had indicated a 2.4 percentage point treatment difference.

The filing indicates that in the pre-specified cardiomyopathy subgroup analysis, the LVEF result remains nominally significant at p=0.02 with a 2.8 percentage point treatment difference. The company states that other additional type-1 error-controlled endpoints will be characterized as nominally significant under applicable hierarchical testing procedures. Notably, the disclosure confirms that the primary efficacy endpoint result and all other trial data remain unchanged from previously reported findings, suggesting the statistical model revision was limited in scope to the LVEF secondary endpoint analysis.

FDA Bioresearch Monitoring Inspection Concludes with Single Observational Citation

Capricor disclosed that on July 4, 2026, the company received notification from the Food and Drug Administration of a Bioresearch Monitoring (BIMO) inspection targeting the company's clinical operations related to its Biologics License Application for Deramiocel in Duchenne muscular dystrophy. The inspection commenced on July 6, 2026, and concluded on July 20, 2026, spanning approximately two weeks of FDA regulatory review of the company's clinical trial conduct and operational procedures.

Upon conclusion of the inspection, the FDA issued a Form FDA 483, Notice of Inspectional Observations, which cited one observation. The filing indicates this observation relates primarily to the company's standard operating procedures, documentation practices, vendor oversight, and audit report timeliness in connection with the conduct of the HOPE-3 clinical trial. The company stated in its disclosure that it does not believe the observation affects the integrity or reliability of the HOPE-3 data. Capricor indicated it is preparing a formal response to the FDA observation and intends to respond completely in a timely manner.

Regulatory Pathway and Clinical Development Timeline

The publication of HOPE-3 results in The Lancet represents a key regulatory milestone in Capricor's clinical development program for Deramiocel. The Phase 3 designation indicates the trial was designed as a pivotal study intended to demonstrate efficacy and safety in support of regulatory approval for commercialization. The one-year follow-up data provides long-term safety and efficacy information critical for regulatory decision-making regarding the investigational therapy in the target patient population with Duchenne muscular dystrophy.

The filing's reference to ongoing FDA dialogue regarding HOPE-3 data suggests the company is engaged in active communication with the regulatory agency regarding the trial results and the company's regulatory submission strategy. The timing of the publication, the FDA inspection, and the disclosure of the statistical model update indicates these regulatory processes were occurring contemporaneously during July 2026, underscoring the intensive regulatory engagement surrounding this investigational cell therapy program.

Deramiocel Development Program in Duchenne Muscular Dystrophy

Deramiocel represents Capricor's lead investigational cell therapy program, with its development focused on treating Duchenne muscular dystrophy, a severe X-linked genetic disorder affecting skeletal, cardiac, and respiratory muscle function. The HOPE-3 trial was designed to evaluate the therapeutic potential of this cell-based approach in this indication. The Phase 3 designation of the trial and the ongoing Biologics License Application underway with the FDA indicate the company has advanced Deramiocel through sufficient preclinical and Phase 1/2 data to justify a pivotal efficacy study in this rare genetic disease.

Duchenne muscular dystrophy is a severe and progressive condition with limited treatment options, representing a significant unmet medical need. The publication of comprehensive one-year HOPE-3 data provides the medical community, including treating physicians, patients, and researchers, with detailed information regarding the safety and efficacy profile of this investigational cell therapy approach in this serious patient population.

Peer Review Process and Scientific Validation

The disclosure emphasizes that the HOPE-3 manuscript underwent independent peer review by The Lancet, one of the world's leading peer-reviewed medical journals. This external scientific review process provides validation of the trial's statistical methodology and the reliability of the published findings. Peer review by leading medical journals serves as a critical quality control mechanism in medical research, with independent experts examining the study design, statistical approaches, data presentation, and conclusions before publication.

The company's identification of the updated statistical model for the LVEF analysis during the peer review process with The Lancet suggests the journal's reviewers conducted rigorous scrutiny of the statistical methods employed in the trial. Such detailed review often uncovers technical considerations or methodological refinements that may not have been apparent during initial data analysis, contributing to the scientific integrity of published medical research.

Statistical Analysis Plan Framework and Regulatory Standards

The filing references the company's prespecified Statistical Analysis Plan version 3.0 (SAP 3.0) as the framework underlying the published HOPE-3 results. Prespecification of statistical analysis plans represents a best practice in clinical trial methodology designed to prevent post-hoc analysis bias and demonstrate analytical transparency. The FDA and international regulatory agencies increasingly require or strongly recommend that pivotal clinical trials be supported by prespecified SAPs established prior to final database lock and statistical analysis.

The disclosure of the SAP 3.0 version number suggests the company had refined its statistical approach through multiple iterations, potentially incorporating feedback from FDA meetings, protocol amendments, or methodological refinements during the trial's conduct. The use of hierarchical testing procedures referenced in the filing indicates the company employed statistical multiplicity control techniques designed to manage type-1 error rates when evaluating multiple endpoints in the HOPE-3 trial.

FDA Form 483 Observations and Company Response Strategy

The FDA Form FDA 483, Notice of Inspectional Observations, represents a standard regulatory communication tool used by FDA investigators to document observations made during facility inspections that do not necessarily constitute formal violations. The single observation cited in the BIMO inspection relates to standard operating procedures, documentation practices, vendor oversight, and audit report timeliness. The company's statement that it does not believe the observation affects the integrity or reliability of the HOPE-3 data suggests management's assessment that the cited items are administrative or process-related rather than substantive scientific matters affecting trial data quality.

The company's commitment to prepare a formal response and address the observation in a timely manner indicates its intention to work cooperatively with the FDA to resolve the inspection findings. The resolution of FDA 483 observations typically occurs through submission of written responses detailing corrective actions taken or explanations provided by the company, followed by FDA review and potential closure of the observation if the agency finds the response satisfactory.

Investment Implications and Regulatory Pathway Forward

The publication of HOPE-3 results in The Lancet and the concurrent FDA BIMO inspection represent significant regulatory developments in Capricor's path toward potential commercialization of Deramiocel. The peer-reviewed publication provides independent scientific validation of the trial data to the medical and investment communities. However, investors may be watching the outcome of the company's response to the single FDA 483 observation to assess whether any regulatory delays or additional requirements may affect the timeline for the FDA's review of the Biologics License Application.

The revision of the LVEF secondary endpoint analysis from p=0.04 to p=0.09, while nominally significant in the cardiomyopathy subgroup, represents a change in the statistical significance of one of the trial's key secondary endpoints. The primary efficacy endpoint result remaining unchanged provides some continuity to the trial's principal findings. Investors may evaluate whether the updated LVEF analysis and the FDA inspection observation create any material impact on the regulatory pathway for Deramiocel or the company's development timelines.